These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2571114)

  • 21. Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial.
    Hatanaka M; Reis A; Sano ME; Susanna R
    J Glaucoma; 2010; 19(5):331-5. PubMed ID: 19730119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase III long-term study and comparative clinical study of nipradilol ophthalmic solution in patients with primary open-angle glaucoma and ocular hypertension.
    Kanno M; Araie M; Masuda K; Takase M; Kitazawa Y; Shiose Y; Azuma I; Ogawa N; Ohdo S
    Arzneimittelforschung; 2006; 56(11):729-34. PubMed ID: 17220049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A combination of levobunolol and dipivefrin for the treatment of glaucoma.
    Allen RC; Robin AL; Long D; Novack GD; Lue JC; Kaplan G
    Arch Ophthalmol; 1988 Jul; 106(7):904-7. PubMed ID: 3291837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of two treatment schedules for combined timolol and dipivefrin therapy.
    Tsoy EA; Meekins BB; Shields MB
    Am J Ophthalmol; 1986 Sep; 102(3):320-4. PubMed ID: 3529971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of ocular hypotensive medication types with dynamic contour tonometry and Goldmann applanation tonometry measurements in a glaucoma and ocular hypertensive population.
    Tzamalis A; Kynigopoulos M; Chalvatzis N; Dimitrakos S; Schlote T
    J Ocul Pharmacol Ther; 2013 Feb; 29(1):41-7. PubMed ID: 23066787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%.
    Kaback M; Scoper SV; Arzeno G; James JE; Hua SY; Salem C; Dickerson JE; Landry TA; Bergamini MV;
    Ophthalmology; 2008 Oct; 115(10):1728-34, 1734.e1-2. PubMed ID: 18538406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levobunolol compared to dipivefrin in African American patients with open angle glaucoma.
    Drake MV; Wilson MR; Harris D; Goodwin L
    J Ocul Pharmacol; 1993; 9(2):91-5. PubMed ID: 8123096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of dorzolamide/timolol and latanoprost/timolol fixed combinations on diurnal intraocular pressure control in primary open-angle glaucoma.
    Eren MH; Gungel H; Altan C; Pasaoglu IB; Sabanci S
    J Ocul Pharmacol Ther; 2012 Aug; 28(4):381-6. PubMed ID: 22320418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levobunolol. A beta-adrenoceptor antagonist effective in the long-term treatment of glaucoma. The Levobunolol Study Group (Appended).
    Ophthalmology; 1985 Sep; 92(9):1271-6. PubMed ID: 2865710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients.
    Costagliola C; Parmeggiani F; Antinozzi PP; Caccavale A; Cotticelli L; Sebastiani A
    Exp Eye Res; 2005 Nov; 81(5):610-5. PubMed ID: 15949795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost.
    Miura K; Ito K; Okawa C; Sugimoto K; Matsunaga K; Uji Y
    J Glaucoma; 2008; 17(3):233-7. PubMed ID: 18414111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Guanethidine/dipivefrin and pilocarpine in the treatment of increased intraocular pressure].
    Ober M; Scharrer A; Dausch D
    Klin Monbl Augenheilkd; 1987 Feb; 190(2):103-4. PubMed ID: 3573660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The additive effect of dipivefrin in patients with wide angle glaucoma treated with long-term beta-blocker therapy in comparison with clonidine].
    Alimgil ML; Erda S; Benian O
    Klin Monbl Augenheilkd; 1994 Aug; 205(2):114-6. PubMed ID: 7967405
    [No Abstract]   [Full Text] [Related]  

  • 34. Additive effect of 1% apraclonidine hydrochloride to nonselective beta-blockers.
    Yaldo MK; Shin DH; Parrow KA; Lee SH; Lee SY
    Ophthalmology; 1991 Jul; 98(7):1075-8. PubMed ID: 1679916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of changing medication regimens in glaucoma patients.
    Novack GD; David R; Lee PF; Freeman MI; Duzman E; Batoosingh AL
    Ophthalmologica; 1988; 196(1):23-8. PubMed ID: 3279366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of adding betaxolol to dipivefrin therapy.
    Weinreb RN; Ritch R; Kushner FH
    Am J Ophthalmol; 1986 Feb; 101(2):196-8. PubMed ID: 3946535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 24-hour control of intraocular pressure with 2% dorzolamide/0.5% timolol fixed-combination ophthalmic solution in open-angle glaucoma.
    Feldman RM; Stewart RH; Stewart WC; Jia G; Smugar SS; Galet VA
    Curr Med Res Opin; 2008 Aug; 24(8):2403-12. PubMed ID: 18627642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy.
    Liu JH; Medeiros FA; Slight JR; Weinreb RN
    Ophthalmology; 2009 Mar; 116(3):449-54. PubMed ID: 19157559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide.
    Clineschmidt CM; Williams RD; Snyder E; Adamsons IA
    Ophthalmology; 1999 Dec; 106(12 Suppl):17-24. PubMed ID: 10598693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of dorzolamide–timolol (COSOPT) in patients who were treatment naive for open-angle glaucoma or ocular hypertension: the COSOPT first-line study.
    Crichton AC; Harasymowycz P; Hutnik CM; Behki R; Boucher S; Ibrahim F; Rifkind AW; Solomon L; Liao C; Bastien NR; Sampalis JS
    J Ocul Pharmacol Ther; 2010 Oct; 26(5):503-11. PubMed ID: 20874498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.